Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urinary Bladder Neoplasms 41Non-Muscle Invasive Bladder Neoplasms 25Carcinoma, Transitional Cell 17Neoplasms 6Urologic Neoplasms 4Urologic Diseases 3Urogenital Neoplasms 3Urinary Bladder Diseases 3Neoplasms by Site 3Carcinoma in Situ 3Carcinoma 3Recurrence 2Virus Diseases 1Urothelial Carcinoma of the Bladder 1Urothelial Carcinoma Ureter 1Urogenital Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Neoplasms by Histologic Type 1Neoplasm Recurrence, Local 1Mycobacterium Infections 1Male Urogenital Diseases 1Female Urogenital Diseases 1Disease 1Adenoviridae Infections 1

Interventions

padeliporfin 5Nivolumab 5Ipilimumab 4Sunitinib 3Specimen Handling 3Mitomycin 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Abiraterone Acetate 3pembrolizumab 2motexafin gadolinium 2enfortumab vedotin 2darolutamide 2cabozantinib 2abiraterone 2Surveys and Questionnaires 2Radiation Dose Hypofractionation 2Pluvicto 2Paclitaxel 2Cisplatin 2Carboplatin 2CTLA-4 Antigen 2vinflunine 1valrubicin 1tislelizumab 1temsirolimus 1sipuleucel-T 1relatlimab 1palladium-bacteriopheophorbide 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urogenital Neoplasms × Mitomycin × Genitourinary × Clear all
NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT05874921 2025-02-28

uTRACT

UroGen Pharma Ltd.

Recruiting
400 enrolled
Genitourinary

Carcinoma, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Recurrence, Urogenital Neoplasms, Urologic Neoplasms

NCT01200992 2017-08-24

EMBARC-RF

Bioniche Life Sciences Inc.

Phase 3 Terminated
84 enrolled 7 charts
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Mycobacterium Infections, Neoplasm Recurrence, Local, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡